This proposal responding to RFA-OD-10-005, 'Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)' fully addresses Research Area 2: Translating Basic Science Discoveries into New and Better Treatments, but also Research Areas 3 (Using Science to Enable Health Care Reform) and 4 (Focusing on Global Health). Infantile spasms (IS) represent a devastating epilepsy syndrome of childhood. IS usually develops between 3-12 months with an incidence of approximately 1 case per 3225 live births. Thus, in the US only there are about 1500 NEW cases of IS, i.e., children who newly require diagnosis and treatment, every year. Worldwide estimate is about 50,000 new patients with IS annually. About 85% of patients with IS become mentally retarded and 67% suffer from intractable epilepsy despite treatment, which is currently mostly hormonal (ACTH, corticosteroids) or vigabatrin, with emergence of new seizure types. IS are associated with significant mortality: about 30% of the patients with IS die mostly during the first 3 years of life. Improvements in therapy of the IS have been severely limited by absence of appropriate animal models for testing new drugs and to study IS mechanisms. Our recently developed model of IS consisting of prenatal priming with betamethasone and postnatal trigger of spasms with NMDA remarkably mimics the human condition: The spastic seizures are age-dependent, associated with EEG electrodecrement and interictal large-amplitude EEG waves, and respond to both acute and long-term treatment with ACTH in a similar way the human IS do. Our follow-up studies revealed several mechanisms that may contribute to the condition of IS: (1) Prenatal priming upregulates expression of melanocortin MC4 receptors in the hypothalamic arcuate nucleus (Arc) one of the brain structures closely linked to the expression of flexion spasms. (2) Prenatal priming upregulates expression of corticotropin releasing factor (CRF) in the Arc. (3) Prenatal priming accelerates developmental switch in replacing NR2B subunit of the NMDA receptor with the NR2A subunit. This proposal will build on these mechanisms to propose three new classes of drug treatment for IS with better efficacy, fewer side effects, and better long-term outcome compared to current IS treatments, with additional substantial cost improvement.
Specific aims of this proposal will determine: (1) Activation of MC4 receptors is an effective therapeutic tool against IS. (2) Blockade or downregulation of CRF receptors-1 is effective against IS. (3) Blockade or downregulation of the NR2A subunit of the NMDA receptor will suppress IS. Methods use prenatal priming with betamethasone and postnatal triggering of spasms with NMDA to model IS. Intracranial microinfusions (icv. and intraparenchymal) of specific siRNAs or receptor agonists/antagonists will determine comparative efficacy versus systemic treatment with ACTH or vigabatrin confirmed by EEG/video monitoring. Behavioral assays will evaluate side effects of new treatments and long-term cognitive outcome.

Public Health Relevance

This proposal fully addresses Research Area 2: Translating Basic Science Discoveries into New and Better Treatments, specifically the infantile spasms (IS), which are a devastating epilepsy syndrome of childhood (about 1500 new cases in the USA per year) currently treated either hormonally (ACTH) at tremendous costs or with vigabatrin with significant side effects but neither treatment improves long-term cognitive outcome, thus over 80% of children become mentally retarded. We have developed and validated a model of IS and determined some basic mechanisms that may contribute to the occurrence of IS. Utilizing these mechanistic findings it is proposed to investigate three new classes of drugs and to develop mechanistic IS therapies, which would become superior in efficacy to the current treatment together with fewer side effects and significant improvement in long-term cognitive outcome, and finally would be incomparably cheaper and safer than currently used drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
High Impact Research and Research Infrastructure Programs—Multi-Yr Funding (RC4)
Project #
7RC4NS072966-02
Application #
8201927
Study Section
Special Emphasis Panel (ZRG1-BDCN-A (55))
Program Officer
Stewart, Randall R
Project Start
2010-09-30
Project End
2013-09-29
Budget Start
2010-12-01
Budget End
2013-09-29
Support Year
2
Fiscal Year
2010
Total Cost
$1,743,324
Indirect Cost
Name
New York Medical College
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
041907486
City
Valhalla
State
NY
Country
United States
Zip Code
10595
Iacobas, Dumitru A; Velíšek, Libor (2018) Regeneration of neurotransmission transcriptome in a model of epileptic encephalopathy after antiinflammatory treatment. Neural Regen Res 13:1715-1718
Iacoba?, Dumitru A; Chachua, Tamar; Iacoba?, Sanda et al. (2018) ACTH and PMX53 recover synaptic transcriptome alterations in a rat model of infantile spasms. Sci Rep 8:5722
Chachua, Tamar; Di Grazia, Paola; Chern, Chian-Ru et al. (2016) Estradiol does not affect spasms in the betamethasone-NMDA rat model of infantile spasms. Epilepsia 57:1326-36
Velíšková, J; Iacobas, D; Iacobas, S et al. (2015) Oestradiol Regulates Neuropeptide Y Release and Gene Coupling with the GABAergic and Glutamatergic Synapses in the Adult Female Rat Dentate Gyrus. J Neuroendocrinol 27:911-20
Shakarjian, Michael P; Ali, Mahil S; Velíšková, Jana et al. (2015) Combined diazepam and MK-801 therapy provides synergistic protection from tetramethylenedisulfotetramine-induced tonic-clonic seizures and lethality in mice. Neurotoxicology 48:100-8
Chachua, T; Goletiani, C; Maglakelidze, G et al. (2014) Sex-specific behavioral traits in the Brd2 mouse model of juvenile myoclonic epilepsy. Genes Brain Behav 13:702-12
Velíšková, Jana; Velíšek, Libor (2013) Gonadal status-dependent effects of in vivo ?-estradiol administration to female rats on in vitro epileptiform activity induced by low [Mg2+]? in combined hippocampus-entorhinal cortex slices. Epilepsy Res 107:297-301
Iacobas, D A; Iacobas, S; Chachua, T et al. (2013) Prenatal corticosteroids modify glutamatergic and GABAergic synapse genomic fabric: Insights from a novel animal model of infantile spasms. J Neuroendocrinol :
Velisek, Libor; Nebieridze, Nino; Chachua, Tamar et al. (2013) Anti-seizure medications and estradiol for neuroprotection in epilepsy: the 2013 update. Recent Pat CNS Drug Discov 8:24-41
Upreti, Chirag; Otero, Rafael; Partida, Carlos et al. (2012) Altered neurotransmitter release, vesicle recycling and presynaptic structure in the pilocarpine model of temporal lobe epilepsy. Brain 135:869-85

Showing the most recent 10 out of 18 publications